View Discovery

Clinical Pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)

GlaxoSmithKline, Bill & Melinda Gates Foundation
TB Alliance, University of Auckland
Shionogi & Co., Ltd
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
TB Alliance, University of Auckland, Merck & Co., Inc.
Microbiotix, Inc.

Phase 1

Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
TB Alliance, Institute of Materia Medica
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF)
GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
MicuRx Pharmaceuticals, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Institute of Materia Medica, CAMS & PUMC

Phase 2

Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Sequella, Inc
Sequella, Inc, TB Alliance
Médecins Sans Frontières
The Aurum Institute NPC, Calibr, The Scripps Research Institute
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP
CDC TBTC, NIAID, NIH, DHHS, Boston University
Weill Medical College of Cornell University

Phase 3

University College, London, SPRINT TB (National University of Singapore)
Médecins Sans Frontières
St. George's Hospital University of London